CancerIQ

CancerIQ is a digital healthcare technology company whose software helps hospitals, health systems and individual providers build and scale cancer risk assessment and precision prevention programs. The platform gathers comprehensive patient data, triages patients into risk tiers using evidence-based guidelines such as NCCN and Tyrer-Cuzick, and streamlines the genetic counseling and testing process by automatically generating pedigrees, offering a marketplace through which providers can order from any testing vendor, producing personalized care plans based on results, and generating supporting documentation such as insurance pre-authorization requests and clinic and progress notes. It also supports longitudinal management of high-risk patients, sending alerts to patients and providers when care management such as breast MRI or colonoscopy is due, and includes patient education content intended to increase uptake and adherence.

The product is organized into four platforms: Navigator (a registry of patients who have completed the screening toolkit, their results and their stated interest in next steps), Specialist (risk assessment workflow for genetic specialists), Manager (tools for managing patients against a risk-based care plan and ongoing engagement), and Analytics (tracking of patients screened, tested and managed, plus preventive services revenue such as breast MRIs and prophylactic mastectomies). CancerIQ can be deployed stand-alone or integrated into EHR workflows via SMART on FHIR apps for Epic and Cerner or direct HL7, so that risk assessment, eligibility determination, test ordering, care planning and follow-up occur inside the chart, drawing on existing EHR data including family history, biopsies, genetic and lab results and medications.

The company has broadened its positioning from pre-diagnosis genetic risk to the full cancer journey, covering genetic testing for BRCA and Lynch syndrome, polygenic risk, breast MRI, multi-cancer early detection, blood-based colon and lung tests, mammography and low-dose CT before diagnosis; biomarker and molecular tumor testing, liquid biopsy and MRD during treatment; and MRD and blood-based surveillance for recurrence monitoring in survivorship.

Founding story

CancerIQ was co-founded in 2013 by Feyi Olopade Ayodele, who took a sabbatical from a career in finance to work alongside her mother, medical oncologist Olufunmilayo (Funmi) Olopade, MD, in the Center for Clinical Cancer Genetics at the University of Chicago. The founders' stated conviction was that the science to detect, prevent and treat cancer should reach every patient who could benefit, with the company's roots in genetic testing.

Business model

CancerIQ sells software to hospitals, health systems and clinics, bundled with a services layer rather than software alone. Every customer receives access to services including launch marketing with white-label tools, patient and provider education, clinical workflow consulting and design, EHR integration, and business planning with benchmarking and multi-year program plans. An additional offering, CancerIQ Complete, provides full-service virtual navigation and genetic counseling, including virtual genetics navigation, education, counseling and care plan follow-up.

Revenue derives from providing software and accompanying implementation, marketing, education and virtual counseling services to provider organizations. The company positions its value proposition around program economics for health systems, citing downstream preventive-services revenue such as breast MRIs and prophylactic mastectomies, more than $160 in downstream revenue per patient screened, and an average 8.9x ROI for health systems.

Traction

Company-reported outcomes include a 2.2x increase in genetic testing completion rates, a 4.2x increase in supplemental screening, and an average 8.9x ROI for health systems. Deployment figures cited across company pages range from over 200 clinic locations and 40+ health systems to 275+ clinics nationwide. A third-party business-data profile lists 21-50 employees and an estimated annual revenue figure.

Latest developments

The company's current site presents an expanded scope spanning prevention, early detection, treatment and survivorship, including multi-cancer early detection, blood-based colon and lung screening, liquid biopsy, biomarker and molecular tumor testing, and MRD-based recurrence surveillance, and reports use by 275+ clinics. It also announced a research initiative to quantify the downstream value of digitally enabled cancer risk programs and is recruiting for open roles.